Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation.
Shock
; 27(2): 113-23, 2007 Feb.
Article
en En
| MEDLINE
| ID: mdl-17224784
ABSTRACT
After the discovery that glycogen synthase kinase (GSK) 3beta plays a fundamental role in the regulation of the activity of nuclear factor kappaB, a number of studies have investigated the effects of this protein kinase in the regulation of the inflammatory process. The GSK-3beta inhibition, using genetically modified cells and chemically different pharmacological inhibitors, affects the regulation of various inflammatory mediators in vitro and in vivo. Insulin, an endogenous inhibitor of GSK-3 in the pathway leading to the regulation of glycogen synthase activity, has recently been clinically used in the therapy for septic shock. The beneficial anti-inflammatory effects of insulin in preclinical and clinical studies could possibly be due, at least in part, to the inhibition of GSK-3 and not directly correlated to the regulation of blood glucose. We describe the latest studies describing the effects of GSK-3 inhibition as potential target of the therapy for diseases associated with inflammation, ischemia/reperfusion, and shock.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Choque
/
FN-kappa B
/
Glucógeno Sintasa
/
Glucógeno Sintasa Quinasa 3
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Shock
Asunto de la revista:
ANGIOLOGIA
/
CARDIOLOGIA
Año:
2007
Tipo del documento:
Article
País de afiliación:
Reino Unido